Toll Free: 18008891064
  • Home
  • About Us
  • Product List
    • ONCOLOGY
      • Cytalux (Pofalacianine)
      • Pylarify (Piflufolastat F18)
      • Truseltiq (Infigratinib)
      • Enhertu (Trastuzumab Deruxtecan)
      • Mektovi (Binimetinib)
      • Braftovi (Encorafenib)
      • Libtayo (Cemiplimab-rwlc)
      • Lorbrena (Lorlatinib)
      • Talzenna (Talazoparib)
      • Balversa (Erdafitinib)
      • Piqray (Alpelisib)
      • Alunbrig (Brigatinib)
      • Jemperli (Dostarlimab-gxly)
      • Tepmetko (Tepotinib)
      • COSELA (Trilaciclib)
      • Fotivda (Tivozanib)
      • Rozlytrek (Entrectinib)
      • Tivdak® (tisotumab vedotin-tftv)
      • Ayvakit (Avapritinib)
      • Tazverik (Tazemetostat)
      • Tukysa (Tucatinib)
      • Pemazyre (Pemigatinib)
      • Trodelvy (Sacituzumab govitecan-hziy)
      • Tabrecta (Capmatinib)
      • Retevmo (Selpercatinib)
      • Zepzelca (Lurbinectedin)
      • Gavreto (Pralsetinib)
      • MARGENZATM (margetuximab-cmkb)
      • Orgovyx (relugolix)
      • DANYELZA (naxitamab-gqgk)
      • ZEJULA (Niraparib)
      • VERZENIO (Abemaciclib)
      • TECENTRIQ (Atezolizumab)
      • NERLYNX (Neratinib)
      • Yervoy
      • CAPRELSA (Vandetnib)
      • CELSENTRI (Maraviroc)
      • CIDOFOVIR (Visitide)
      • IBRANCE (Palbociclib Capsules)
      • COMETRIQ (Cabozantinib)
      • CYRAMZA (Ramucirumab Injection)
      • DABRAFENIB (Tafinlar)
      • ENTEREG (Almiopan Capsule)
      • ERIVEDGE (Vismodegib Tablet)
      • LYNPARZA (Olaparib)
      • Qinlock (Ripretinib)
      • MEKINIST (Trametnib Tablet)
      • Mitotane (Lysodren)
      • NAVELBINE ORAL (Vinorelbine)
      • TEYSUNO (Tegafur)
      • ZELBORAF (Vemurafenib Tablet)
      • Zepzelca (Lurbinectedin)
      • ZYDELIG (Idelalisib)
    • HEMATOLOGY
      • Rezurock (Belumosudil)
      • Empaveli (Pegcetacoplan)
      • Idhifa (Enasidenib)
      • Besponsa (Inotuzumab Ozogamicin)
      • Tibsovo (Ivosidenib)
      • Poteligeo (Mogamulizumab-kpkc)
      • Xospata (Gilteritinib)
      • Asparlas (Calaspargase pegol-mknl)
      • Polivy (Polatuzumab Vedotin-piiqa
      • Reblozyl (Luspatercept–aamt)
      • Ukoniq (Umbralisib)
      • Pepaxto (Melphalan Flufenamide)
      • Zynlonta (Loncastuximab Tesirine-lpyl)
      • Rylaze
      • Exkivity (Mobocertinib)
      • SCEMBLIX®(Asciminib)
      • Besremi (Ropeginterferon alfa-2b-njft)
      • SARCLISA® (isatuximab-irfc)
      • Inqovi (decitabine and cedazuridine)
      • Blenrep (Belantamab Mafodotin-blmf)
      • Monjuvi (Tafasitamab-cxix)
      • TAFINLAR (Dabrafenib)
      • CALQUENCE (Acalabrutinib)
      • MYLOTARG Gemtuzumab
      • Aliqopa(Copanlisib)
      • Brentuximab Vedotin
      • AGRYLIN (Anagrelide Hydrochloride)
      • ATRIANCE (Nelarabine)
      • BLINCYTO (Blinatumomab)
      • ONCASPAR (Pegaspargase)
      • ERWINAZE (Asparaginase Erwinia Chrysanthemi)
      • FOLOTYN (Pralatrexate)
      • TREOSULFAN (Treosulfan)
      • Ponatinib
      • NPLATE (Romiplostim)
      • KYPROLIS (Carfilzomib)
      • MABCAMPATH (Alemtuzumab)
      • VENCLEXTA (Venetoclax)
      • SOLIRIS (eculizumab)
      • SYNRIBO (Omacetaxine Mepesuccinate)
      • ALKERAN (Melphalan)
      • FARYDAK (Panobinostat)
      • BOSULIF (Bosutinib)
      • ELDISINE (Vindesine Sulphate)
      • Ixazomib Citrate
      • TEPADINA (Thiotepa)
      • ZOLINZA (Vorinostat)
    • Nephrology
      • Ultomiris (Ravulizumab)
    • GASTROENTROLOGY
      • VOSEVI (Sofosbuvir, Velpatasvir, And Voxilaprevir)
      • OLYSIO (SIMEPREVIR)
      • SYPRINE (Trientine HCL)
    • NEUROLOGY
      • Azstarys (Serdexmethylphenidate and Dexmethylphenidate)
      • Qelbree (Viloxazine)
      • Lybalvi (Olanzapine and Samidorphan)
      • Aduhelm (aducanumab-avwa)
      • NUEDEXTA (Dextromethorphan Hydrobromide)
      • ILARIS (Canakinumab)
      • GLIOLAN (Aminolevulinic acid hydrochloride)
      • STELARA (Ustekinumab)
      • HUMIRA (Adalimumab)
    • IMMUNOLOGY
      • Ocrevus (Ocrelizumab)
      • Skyrizi (Risankizumab-rzaa)
      • PONVORY®(ponesimod)
      • Zeposia (Ozanimod)
      • SILIQ (Brodalumab)
      • TREMFYA (Guselkumab)
    • RARE DISEASES
      • Nulibry (Fosdenopterin)
      • Welireg (Belzutifan)
      • Xiaflex (Collagenase Clostridium Histolyticum)
      • Mepsevii (Vestronidase alfa-vjbk)
      • Symdeko (Tezacaftor/Ivacaftor & Ivacaftor)
      • Palynziq (Pegvaliase-pqpz)
      • Onpattro (Patisiran)
      • Galafold (Migalastat)
      • Diacomit (Stiripentol)
      • Takhzyro (Lanadelumab)
      • Orfadin (Nitisinone)
      • Trikafta (elexacaftor, tezacaftor and ivacaftor)
      • Spinraza (Nusinersen)
      • Amondys 45 (Casimersen)
      • Voxzogo (Vosoritide)
      • Tepezza (Teprotumumab-trbw)
      • Isturisa (Osilodrostat)
      • Koselugo (Selumetinib)
      • VILTEPSO (Viltolarsen)
      • XERMELO (Telotristat)
      • BRINUERA(Cerliponase alfa)
      • MEPSEVII (Vestronidase)
      • PARSABIV (Etelcalcetide)
      • RADICAVA (Edaravone)
      • RHOPRESSA (Netarsudil)
    • Cardio
      • Vyndaqel (tafamidis meglumine)
    • MISC.
      • Brexafemme (Ibrexafungerp)
      • Qulipta Atogepant
      • Zemdri (Plazomicin)
      • Epidiolex (Cannabidiol)
      • ZAVICEFTA (Avibactum + Ceftazidime)
      • BAXDELA (Delafloxacin)
      • BEVYXXA (Betrixaban)
      • FASENRA (Benralizumab)
      • FIRAZYR (Icatibant)
      • KEVZARA(Sarilumab)
      • TRULANCE (Plecanatide)
      • VIVITROL (Naltrexone)
      • XADAGO (Safinamide)
      • Foscavir (Foscarnet sodium injection)
      • Anakinra (Kineret)
      • PADCEV (Enfortumab Vedotin-ejfv)
      • Lonsurf (Trifluridine/Tipiracil)
      • Dantrium IV (Dantrolene Sodium)
  • Blog
  • Contact Us

Drug & Cosmetic Act And Rules: INDIA

What are the Drug & Cosmetic Act and Rules 1940?

The Drug & Cosmetic Act and Rules 1940 was enacted by the Department of Health under the Ministry of Health and Family Welfare after receiving the consent of the Governor General on April 10, 1940, and came into force on April 1, 1947. This Act regulates the manufacture, distribution and sale of drugs, biosimilars, medical devices and importers in India. The first and foremost objective of the Act is to ensure that the drugs, biosimilars and medical devices sold in India are safe, effective and conform to state quality standards. The original version of the Act has 5 Chapters, 38 Sections and 2 schedules.

Health is a Fundamental Right granted by the Constitution of India. The Drugs Control Administration aims to assure the availability of drugs & Cosmetics of proven quality, efficacy and safety at prices as announced. In addition, it also guards the public against the exploitation of misleading advertisements.

The government of India establishes the Rules through the Drugs and Cosmetics Act of 1940. The Rules have also been amended from time to time to meet the needs of the time and to rectify any deficiencies noticed during the implementation:

  • The Drugs and Cosmetics Rules, 1945
  • The New Drugs and Cosmetics Rules, 2019
The goals of the Drug & Cosmetic Act and Rules 1940 are:
  • To regulate the import, manufacture, distribution and sale of drugs & cosmetics through licensing.
  • Manufacture, distribution and sale of drugs and cosmetics by qualified persons only.
  • To avoid substandard drugs, presumably to maintain high standards of medical treatment.
  • To regulate the manufacture and sale of Ayurvedic, Siddha and Unani medicines.
  • To establish the Drugs Technical Advisory Board (DTAB) and Drugs Consultative Committees (DCC) for Allopathic and allied drugs and cosmetics.
Schedules of Drug & & Cosmetic Act 1940

First Schedule- Names of books under Ayurvedic and Siddha systems.
Second Schedule– Standard to be compiled with imported drugs and by drugs manufactured for sale, sold, stocked or exhibited for sale or distribution.
Drug & Cosmetic Rules, 1945
The Drugs and Cosmetics Rules of 1945 are the rules the government of India established through the Drugs and Cosmetics Act of 1940. These rules catogrize drugs under given schedules and present guidelines for each schedule’s storage, sale, display, and prescription. The drug rules were promulgated in December 1945, and enforcement started in 1947. 
The rules comprise 19 Parts and 20 schedules. Parts IV, part VII, part VIII and part IX state rules and regulations for importing, manufacturing, and selling drugs and biological and medical devices. Part X explains provisions solely applicable to biological products. Part X describes naming, container, labeling, and standards related to the quality and testing of biological products.
Schedules of Drug & & Cosmetic Rule 1945
And enforcement started in 1947. These Rules have been amended from time to time to meet the needs and to rectify any shortcomings in the process.
SCHEDULE – A – FORMS
SCHEDULE – B – Fee for Test or Analysis
SCHEDULE- C –Biological & Special Products
SCHEDULE – C1- Other Special Products
SCHEDULE- D –Exemptions u. c. III
SCHEDULE- D(I)- Information –Mfg. Unit Registration for import D&C RULES contd.,
Schedule – D(II)-Information –product Registration for import
SCHEDULE- E(1) – Poisonous Substances
SCHEDULE F – PART I to PART XII(A) OMITTED
PART XII – B – Blood &Blood BANKS
PART XII – C – BLOOD PRODUCTS.
SCHEDULE F(1) – Bacterial Vaccines, Sera
SCHEDULE F(II) – Standards, Surgical Dressings
SCHEDULE F(III) – Standards Umbilical Tapes
SCHEDULE FF – Standards Ophthalmic preparations
SCHEDULE G – Drugs to be used under the supervision of Regd.Medical Practitioners.
SCHEDULE H – Prescription Drugs
SCHEDULE J – Prohibition of advertisements on drugs.
SCHEDULE K – Exemptions-Chap IV
SCHEDULE L1 – Good Laboratory practices.
SCHEDULE M – Good Mfg Practices
SCHEDULE M-I –GMP Homeo Medicines
SCHEDULE M II – Factory-cosmetics
SCHEDULE M III -Factory Medical Devices
SCHEDULE N – Pharmacy- requirements
SCHEDULE O – Standards for Disinfectant fluids
SCHEDULE P – Life Period of drugs
SCHEDULE P 1 –Pack size of drugs
SCHEDULE Q– Colours Cosmetics
SCHEDULE R- Standards for Condoms
SCHEDULE R1-Stds for Medical Devices
SCHEDULE S– Standards for cosmetics
SCHEDULE T-GMP- Ayurvedic Drugs
SCHEDULE U – RECORDS-DRUGS
SCHEDULE U1- Records Cosmetics
SCHEDULE V- Stds for P&P Medicines
SCHEDULE X- Class of Drugs- XRx
SCHEDULE Y- Requirements and Guidelines for permission to import and manufacture New Drugs for sale or undertake Clinical Trials.
New Drugs and Clinical Trials Rules 2019
The New drugs and Clinical trials rule 2019 (New rules) was introduced on March 19, 2019, by the Government of India vide Gazette of India Notification #227 dated March 19, 2019. The new rules aim to promote clinical research in the country and will change the regulatory landscape for the approval of new drugs and the conduct of clinical trials in the country. The new regulations cover provisions for promoting clinical research and complex topics such as orphan drugs, post-trial access, and pre and post-submission meetings. The new rules are structured around 13 chapters (including 107 rules) and eight schedules. The new rules will apply to all biological products (human vaccines and rDNA products) except for stem cell and cell-based Products and Veterinary vaccines.

Reference: https://cliniexperts.com/india-regulatory-bodies/cdsco/drug-and-cosmetic-act-1940_drugs-and-cosmetic-rules-1945_drugs-and-cosmetic-rules-2019/
http://www.mcrhrdi.gov.in/drugs/material/drugs%20control.pdf
  • Posted by admin
  • On January 31, 2023
  • 0 Comments
  • 0 likes
Tags: Drug & Cosmetic Act, Drug & Cosmetic Act And Rules: INDIA, name patient import, name patient import supplier, named patient supplier in india

0 Comments

Leave Reply Cancel reply

You must be logged in to post a comment.

Archives
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • October 2021
Categories
  • Achondroplasia (1)
  • acute lymphocytic leukemia (4)
  • Adrenal Cancer (1)
  • adrenal gland (1)
  • Bladder Cancer (3)
  • blood cancer (2)
  • Breast Cancer (9)
  • Chronic Lymphocytic Leukemia (2)
  • CMV (1)
  • Crohn’s disease (1)
  • DLBCL (1)
  • Drug & Cosmetic Act (1)
  • Enhertu (2)
  • hereditary tyrosinemia (1)
  • Hodgkin Lymphoma (4)
  • leukaemia (2)
  • Metastatic Breast Cancer (3)
  • metastatic colorectal cancer (2)
  • name patient import (1)
  • named patient program india (2)
  • NSCLC (1)
  • PNH (2)
  • RETEVMO (1)
  • rheumatoid arthritis (1)
  • Stomach Gastric Cancer (1)
  • T-cell Acute Lymphoblastic Leukaemia (1)
  • thyroid carcinoma (2)
  • Uncategorized (1)
Archives
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • October 2021
Popular Posts
  • Understanding Rheumatoid Arthritis (RA)December 20, 2021
  • Nelarabine : Drug Information for PatientsOctober 29, 2021
  • Blincyto Treatment for Acute Lymphoblastic LeukemiaDecember 3, 2021
Photo Stream

Nelarabine : Drug Information for Patients

Previous thumb

Hodgkin's Lymphoma Treatment

Next thumb
Scroll

Indian Pharma Network helps in accessing new products in India. These products are launched and approved recently in USA or Europe but yet to be approved in India. We help in accessing these new launches through named patient import.

Quick Links
  • Home
  • About Us
  • Blog
  • Contact us
About Us

Indian Pharma Network facilitates patients connecting with genuine pharmaceutical suppliers, wholesalers and dealers.

Indian Pharma Network.
info@indianpharmanetwork.in
Corporate Office
Indian Pharma Network.
905 – 9th Floor, I-Thum Business Park,
Tower A, Plot no. A-40, Unit no. 5,
Sector-62, Noida 201301,
info@indianpharmanetwork.in
  • +91 9310090915

  • @2022 All Right Reserved indianpharmanetwork

    WhatsApp us

    • Home
    • About Us
    • Product List
      • ONCOLOGY
        • Cytalux (Pofalacianine)
        • Pylarify (Piflufolastat F18)
        • Truseltiq (Infigratinib)
        • Enhertu (Trastuzumab Deruxtecan)
        • Mektovi (Binimetinib)
        • Braftovi (Encorafenib)
        • Libtayo (Cemiplimab-rwlc)
        • Lorbrena (Lorlatinib)
        • Talzenna (Talazoparib)
        • Balversa (Erdafitinib)
        • Piqray (Alpelisib)
        • Alunbrig (Brigatinib)
        • Jemperli (Dostarlimab-gxly)
        • Tepmetko (Tepotinib)
        • COSELA (Trilaciclib)
        • Fotivda (Tivozanib)
        • Rozlytrek (Entrectinib)
        • Tivdak® (tisotumab vedotin-tftv)
        • Ayvakit (Avapritinib)
        • Tazverik (Tazemetostat)
        • Tukysa (Tucatinib)
        • Pemazyre (Pemigatinib)
        • Trodelvy (Sacituzumab govitecan-hziy)
        • Tabrecta (Capmatinib)
        • Retevmo (Selpercatinib)
        • Zepzelca (Lurbinectedin)
        • Gavreto (Pralsetinib)
        • MARGENZATM (margetuximab-cmkb)
        • Orgovyx (relugolix)
        • DANYELZA (naxitamab-gqgk)
        • ZEJULA (Niraparib)
        • VERZENIO (Abemaciclib)
        • TECENTRIQ (Atezolizumab)
        • NERLYNX (Neratinib)
        • Yervoy
        • CAPRELSA (Vandetnib)
        • CELSENTRI (Maraviroc)
        • CIDOFOVIR (Visitide)
        • IBRANCE (Palbociclib Capsules)
        • COMETRIQ (Cabozantinib)
        • CYRAMZA (Ramucirumab Injection)
        • DABRAFENIB (Tafinlar)
        • ENTEREG (Almiopan Capsule)
        • ERIVEDGE (Vismodegib Tablet)
        • LYNPARZA (Olaparib)
        • Qinlock (Ripretinib)
        • MEKINIST (Trametnib Tablet)
        • Mitotane (Lysodren)
        • NAVELBINE ORAL (Vinorelbine)
        • TEYSUNO (Tegafur)
        • ZELBORAF (Vemurafenib Tablet)
        • Zepzelca (Lurbinectedin)
        • ZYDELIG (Idelalisib)
      • HEMATOLOGY
        • Rezurock (Belumosudil)
        • Empaveli (Pegcetacoplan)
        • Idhifa (Enasidenib)
        • Besponsa (Inotuzumab Ozogamicin)
        • Tibsovo (Ivosidenib)
        • Poteligeo (Mogamulizumab-kpkc)
        • Xospata (Gilteritinib)
        • Asparlas (Calaspargase pegol-mknl)
        • Polivy (Polatuzumab Vedotin-piiqa
        • Reblozyl (Luspatercept–aamt)
        • Ukoniq (Umbralisib)
        • Pepaxto (Melphalan Flufenamide)
        • Zynlonta (Loncastuximab Tesirine-lpyl)
        • Rylaze
        • Exkivity (Mobocertinib)
        • SCEMBLIX®(Asciminib)
        • Besremi (Ropeginterferon alfa-2b-njft)
        • SARCLISA® (isatuximab-irfc)
        • Inqovi (decitabine and cedazuridine)
        • Blenrep (Belantamab Mafodotin-blmf)
        • Monjuvi (Tafasitamab-cxix)
        • TAFINLAR (Dabrafenib)
        • CALQUENCE (Acalabrutinib)
        • MYLOTARG Gemtuzumab
        • Aliqopa(Copanlisib)
        • Brentuximab Vedotin
        • AGRYLIN (Anagrelide Hydrochloride)
        • ATRIANCE (Nelarabine)
        • BLINCYTO (Blinatumomab)
        • ONCASPAR (Pegaspargase)
        • ERWINAZE (Asparaginase Erwinia Chrysanthemi)
        • FOLOTYN (Pralatrexate)
        • TREOSULFAN (Treosulfan)
        • Ponatinib
        • NPLATE (Romiplostim)
        • KYPROLIS (Carfilzomib)
        • MABCAMPATH (Alemtuzumab)
        • VENCLEXTA (Venetoclax)
        • SOLIRIS (eculizumab)
        • SYNRIBO (Omacetaxine Mepesuccinate)
        • ALKERAN (Melphalan)
        • FARYDAK (Panobinostat)
        • BOSULIF (Bosutinib)
        • ELDISINE (Vindesine Sulphate)
        • Ixazomib Citrate
        • TEPADINA (Thiotepa)
        • ZOLINZA (Vorinostat)
      • Nephrology
        • Ultomiris (Ravulizumab)
      • GASTROENTROLOGY
        • VOSEVI (Sofosbuvir, Velpatasvir, And Voxilaprevir)
        • OLYSIO (SIMEPREVIR)
        • SYPRINE (Trientine HCL)
      • NEUROLOGY
        • Azstarys (Serdexmethylphenidate and Dexmethylphenidate)
        • Qelbree (Viloxazine)
        • Lybalvi (Olanzapine and Samidorphan)
        • Aduhelm (aducanumab-avwa)
        • NUEDEXTA (Dextromethorphan Hydrobromide)
        • ILARIS (Canakinumab)
        • GLIOLAN (Aminolevulinic acid hydrochloride)
        • STELARA (Ustekinumab)
        • HUMIRA (Adalimumab)
      • IMMUNOLOGY
        • Ocrevus (Ocrelizumab)
        • Skyrizi (Risankizumab-rzaa)
        • PONVORY®(ponesimod)
        • Zeposia (Ozanimod)
        • SILIQ (Brodalumab)
        • TREMFYA (Guselkumab)
      • RARE DISEASES
        • Nulibry (Fosdenopterin)
        • Welireg (Belzutifan)
        • Xiaflex (Collagenase Clostridium Histolyticum)
        • Mepsevii (Vestronidase alfa-vjbk)
        • Symdeko (Tezacaftor/Ivacaftor & Ivacaftor)
        • Palynziq (Pegvaliase-pqpz)
        • Onpattro (Patisiran)
        • Galafold (Migalastat)
        • Diacomit (Stiripentol)
        • Takhzyro (Lanadelumab)
        • Orfadin (Nitisinone)
        • Trikafta (elexacaftor, tezacaftor and ivacaftor)
        • Spinraza (Nusinersen)
        • Amondys 45 (Casimersen)
        • Voxzogo (Vosoritide)
        • Tepezza (Teprotumumab-trbw)
        • Isturisa (Osilodrostat)
        • Koselugo (Selumetinib)
        • VILTEPSO (Viltolarsen)
        • XERMELO (Telotristat)
        • BRINUERA(Cerliponase alfa)
        • MEPSEVII (Vestronidase)
        • PARSABIV (Etelcalcetide)
        • RADICAVA (Edaravone)
        • RHOPRESSA (Netarsudil)
      • Cardio
        • Vyndaqel (tafamidis meglumine)
      • MISC.
        • Brexafemme (Ibrexafungerp)
        • Qulipta Atogepant
        • Zemdri (Plazomicin)
        • Epidiolex (Cannabidiol)
        • ZAVICEFTA (Avibactum + Ceftazidime)
        • BAXDELA (Delafloxacin)
        • BEVYXXA (Betrixaban)
        • FASENRA (Benralizumab)
        • FIRAZYR (Icatibant)
        • KEVZARA(Sarilumab)
        • TRULANCE (Plecanatide)
        • VIVITROL (Naltrexone)
        • XADAGO (Safinamide)
        • Foscavir (Foscarnet sodium injection)
        • Anakinra (Kineret)
        • PADCEV (Enfortumab Vedotin-ejfv)
        • Lonsurf (Trifluridine/Tipiracil)
        • Dantrium IV (Dantrolene Sodium)
    • Blog
    • Contact Us